Dr. Rudnick is a Venture Partner at Canaan Partners, managing healthcare investments. He has led many drug discovery and development projects throughout his career in the pharmaceutical and biotech industries, which spans research, development, clinical trials analysis and biotechnology as well as founding and growing start-up companies. Prior to joining Canaan Partners, Dr. Rudnick served as Chief Executive Officer and Chairman of CytoTherapeutics, a company developing stem cell-based therapies to combat chronic diseases. He also helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson that provides life-improving products to individuals with a focus on cancer and chronic illnesses. He is currently a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill, teaching and advising faculty members on biotechnology issues.

"We are pleased to welcome Dr. Rudnick to the POZEN Board of Directors," said Dr. John R. Plachetka, Chairman, President and Chief Executive Officer of POZEN. "His deep experience in pharmaceutical development and life sciences investment experience will be an asset to us as we embark on our new strategy."

Comments

Search RSS

All rights reserved."